There are 2934 resources available
Proffered Paper – Melanoma and other skin tumours - Invited Discussant LBA66, LBA67 and 1310O
Presenter: Bartosz Chmielowski
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Slides
Webcast
2545 - 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma
Presenter: James Larkin
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1900 - Initial Results From TROPHY-U-01: A Phase 2 Open-Label Study of Sacituzumab Govitecan in Patients (Pts) With Metastatic Urothelial Cancer (mUC) After Failure of Platinum-Based Regimens (PLT) or Immunotherapy
Presenter: Scott Tagawa
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Proffered Paper 1 – Genitourinary tumours, non-prostate - Invited Discussant LBA54 and LBA55
Presenter: Ignacio Duran Martinez
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Proffered Paper 1 – Genitourinary tumours, non-prostate - Invited Discussant 901O and 902O
Presenter: Yohann Loriot
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
4844 - EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Presenter: Christopher Hoimes
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
4397 - An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies
Presenter: Thomas Powles
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
2801 - Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
3661 - Long-term Outcomes from the Randomized Ph 2 Study of Nivolumab (nivo) or Nivo+Ipilimumab (ipi) in Patients (pts) with Melanoma Brain Metastases (mets): Anti-PD1 Brain Collaboration (ABC)
Presenter: Georgina Long
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1691 - PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors
Presenter: Benedetta Pellegrino
Session: Proffered Paper – Translational research
Resources:
Abstract
Slides
Webcast